296
Participants
Start Date
May 31, 2005
Primary Completion Date
October 31, 2006
Study Completion Date
October 31, 2006
MN-001 BID
Eligible patients received 500 mg MN-001 bid
MN-001
Eligible patients received 500 mg MN-001 once daily (qd)
Placebo
Eligible patients received placebo
Upstate Urology, Albany
Lyndhurst Gynecology Associates, Winston-Salem
The Urology Group, Greer
Shepherd Center, Inc., Atlanta
Segal Institute for Clinical Research, Aventura
Adult and Pediatric Urology, Plantation
Georgis Patsias, MD., PA, Wellington
Visions Clinical Research, Boynton Beach
West Florida Urology, Palm Harbor
MediciNova Investigational Site, Birmingham
Tristate Urologic Services PSC., Inc., Cincinnati
Midwest Regional Center For Chronic Pelvic Pain and Bladder Control, Lima
William Beaumont Hospital, Royal Oak
Evanston Continence Center, Evanston
Center For Advanced Pelvic Surgery, Centralia
Regional Urology, LLC, Shreveport
Medical Arts Clinic, Corsicana
Gant Foundation, Fort Worth
Western Urologic Research Center, Wheat Ridge
Boulder Medical Center, P.C., Boulder
Brian Heaton, MD, Ogden
Sheldon J. Freedman, MD, LTD, Las Vegas
Atlantic Urological Medical Group, Long Beach
Citrus Valley Urological Medical Group, Glendora
Mendez Transplant and Urological Medical Group, San Diego
Williamette Women's Healthcare P.C., Tualatin
Integrity Medical Research, LLC, Mountlake Terrace
Associated Urologic Specialists, P.A., Marlton
Lead Sponsor
MediciNova
INDUSTRY